Comparative Pharmacology
Head-to-head clinical analysis: ANTRENYL versus PROPANTHELINE BROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTRENYL versus PROPANTHELINE BROMIDE.
ANTRENYL vs PROPANTHELINE BROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antrenyl (oxyphenonium bromide) is a quaternary ammonium anticholinergic agent that competitively blocks acetylcholine at muscarinic receptors in smooth muscle, exocrine glands, and the CNS, leading to reduced gastrointestinal motility and secretion.
Antimuscarinic; competitively blocks acetylcholine at postganglionic muscarinic receptors, inhibiting parasympathetic nerve impulses.
50 mg orally 3 times daily initially, then adjust to 50-100 mg 3 times daily; 20 mg intramuscularly or intravenously every 4-6 hours as needed.
15 mg orally 3 times daily before meals and 30 mg at bedtime; initial dose may be 15 mg 3 times daily.
None Documented
None Documented
2-4 hours (terminal), requiring q6-8h dosing for sustained anticholinergic effect
Terminal half-life 2.5-4 hours; clinically, dosing every 6 hours maintains therapeutic levels.
Renal (80% as unchanged drug and metabolites), biliary/fecal (20%)
Approximately 70% renal (tubular secretion) as metabolites and unchanged drug; 30% biliary/fecal.
Category C
Category A/B
Anticholinergic
Anticholinergic